We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
INOVELON (Eisai Australia Pty Ltd)
Product name
INOVELON
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
240 working days (255)
Active ingredients
rufinamide
Registration type
NCE/NBE
Indication
INOVELON (film-coated tablets) is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.